| Biological Sciences | Lifetime | 769 | CN 22 | 99.91 |
| Biological Sciences | 2021-2025 | 12 | CN 3 | 99.98 |
| Medical and Health Sciences | 2021-2025 | 71 | CN 6 | 99.99 |
| Cancer Research | Lifetime | 81 | CN 1 | 99.57 |
| Molecular Biology | Lifetime | 573 | CN 22 | 99.72 |
| Oncology | Lifetime | 259 | CN 5 | 99.58 |
| Pulmonary and Respiratory Medicine | Lifetime | 584 | CN 9 | 99.16 |
| Immunology | Lifetime | 454 | CN 11 | 98.76 |
| Pathology and Forensic Medicine | Lifetime | 409 | CN 5 | 98.33 |
| Clinical Pharmacology | Lifetime | 517 | CN 13 | 97.82 |
| Hepatology | Lifetime | 640 | CN 39 | 90.38 |
| Molecular Biology | 2021-2025 | 12 | CN 6 | 99.94 |
| Cancer Research | 2021-2025 | 3 | CN 2 | 99.89 |
| Immunology | 2021-2025 | 11 | CN 2 | 99.72 |
| Oncology | 2021-2025 | 27 | CN 3 | 99.85 |
| Pulmonary and Respiratory Medicine | 2021-2025 | 50 | CN 8 | 99.75 |
| Surgery | 2021-2025 | 118 | CN 8 | 99.32 |
| Epidemiology | 2021-2025 | 155 | CN 18 | 99.00 |
| Pathology and Forensic Medicine | 2021-2025 | 64 | CN 3 | 98.57 |
| Clinical Pharmacology | 2021-2025 | 212 | CN 16 | 92.19 |
| Genetics | 2021-2025 | 405 | CN 31 | 89.02 |
| Radiology, Nuclear Medicine and Imaging | 2021-2025 | 591 | CN 68 | 87.30 |
| Medical Physiology | 2021-2025 | 820 | CN 57 | 86.42 |
| Infectious Diseases | 2021-2025 | 668 | CN 64 | 84.56 |
| Cardiology and Cardiovascular Medicine | 2021-2025 | 768 | CN 37 | 85.41 |
| Hepatology | 2021-2025 | 258 | CN 20 | 84.45 |
| Cancer-related molecular mechanisms research | Lifetime | 21 | CN 6 | 99.81 |
| Ferroptosis and cancer prognosis | Lifetime | 11 | CN 3 | 99.67 |
| Circular RNAs in diseases | Lifetime | 18 | CN 7 | 99.73 |
| MicroRNA in disease regulation | Lifetime | 39 | CN 10 | 99.75 |
| RNA modifications and cancer | Lifetime | 188 | CN 15 | 99.49 |
| Cancer Immunotherapy and Biomarkers | Lifetime | 167 | CN 6 | 99.57 |
| Immune cells in cancer | Lifetime | 109 | CN 7 | 99.25 |
| Cancer Mechanisms and Therapy | Lifetime | 141 | CN 14 | 98.43 |
| Epigenetics and DNA Methylation | Lifetime | 655 | CN 51 | 98.46 |
| interferon and immune responses | Lifetime | 243 | CN 15 | 98.27 |
| Lung Cancer Research Studies | Lifetime | 345 | CN 10 | 98.63 |
| Cancer Treatment and Pharmacology | Lifetime | 440 | CN 2 | 98.74 |
| Lung Cancer Treatments and Mutations | Lifetime | 651 | CN 37 | 98.62 |
| RNA Research and Splicing | Lifetime | 715 | CN 23 | 98.07 |
| Inflammasome and immune disorders | Lifetime | 224 | CN 13 | 97.61 |
| Cancer, Lipids, and Metabolism | Lifetime | 502 | CN 12 | 98.13 |
| Inflammatory mediators and NSAID effects | Lifetime | 412 | CN 12 | 97.54 |
| Cancer-related gene regulation | Lifetime | 545 | CN 62 | 97.43 |
| Cancer, Stress, Anesthesia, and Immune Response | Lifetime | 164 | CN 8 | 96.19 |
| Cytokine Signaling Pathways and Interactions | Lifetime | 482 | CN 26 | 97.45 |
| Biomarkers in Disease Mechanisms | Lifetime | 104 | CN 3 | 95.61 |
| Chemokine receptors and signaling | Lifetime | 303 | CN 8 | 95.63 |
| Extracellular vesicles in disease | Lifetime | 884 | CN 309 | 94.21 |
| Advanced Breast Cancer Therapies | Lifetime | 606 | CN 20 | 95.29 |
| Multiple and Secondary Primary Cancers | Lifetime | 806 | CN 13 | 92.73 |
| IL-33, ST2, and ILC Pathways | Lifetime | 940 | CN 40 | 92.41 |
| Wnt/β-catenin signaling in development and cancer | Lifetime | 921 | CN 52 | 92.01 |
| Kruppel-like factors research | Lifetime | 686 | CN 84 | 89.53 |
| Phagocytosis and Immune Regulation | Lifetime | 876 | CN 64 | 89.62 |
| Mechanisms of cancer metastasis | Lifetime | 204 | CN 31 | 85.37 |
| Spinal Hematomas and Complications | Lifetime | 962 | CN 56 | 80.02 |
| Cancer-related molecular mechanisms research | 2021-2025 | 5 | CN 2 | 99.94 |
| RNA modifications and cancer | 2021-2025 | 7 | CN 5 | 99.90 |
| Ferroptosis and cancer prognosis | 2021-2025 | 6 | CN 4 | 99.84 |
| Immune cells in cancer | 2021-2025 | 6 | CN 4 | 99.68 |
| Epigenetics and DNA Methylation | 2021-2025 | 21 | CN 8 | 99.10 |
| Cancer Immunotherapy and Biomarkers | 2021-2025 | 52 | CN 7 | 99.79 |
| Immune Cell Function and Interaction | 2021-2025 | 41 | CN 7 | 99.16 |
| Cancer-related gene regulation | 2021-2025 | 11 | CN 7 | 99.03 |
| Circular RNAs in diseases | 2021-2025 | 21 | CN 13 | 99.37 |
| Cancer Mechanisms and Therapy | 2021-2025 | 13 | CN 5 | 98.33 |
| MicroRNA in disease regulation | 2021-2025 | 91 | CN 60 | 98.50 |
| RNA Research and Splicing | 2021-2025 | 67 | CN 19 | 97.57 |
| Cancer Genomics and Diagnostics | 2021-2025 | 232 | CN 15 | 98.24 |
| Inflammasome and immune disorders | 2021-2025 | 74 | CN 34 | 96.28 |
| Cancer Treatment and Pharmacology | 2021-2025 | 82 | CN 5 | 98.43 |
| Cancer, Hypoxia, and Metabolism | 2021-2025 | 143 | CN 60 | 95.83 |
| Esophageal Cancer Research and Treatment | 2021-2025 | 156 | CN 32 | 96.52 |
| Lung Cancer Research Studies | 2021-2025 | 187 | CN 32 | 97.58 |
| Immunotherapy and Immune Responses | 2021-2025 | 364 | CN 103 | 95.40 |
| interferon and immune responses | 2021-2025 | 122 | CN 63 | 93.85 |
| Cytokine Signaling Pathways and Interactions | 2021-2025 | 59 | CN 5 | 92.67 |
| CAR-T cell therapy research | 2021-2025 | 576 | CN 56 | 96.54 |
| Genetic factors in colorectal cancer | 2021-2025 | 232 | CN 17 | 95.07 |
| Lung Cancer Treatments and Mutations | 2021-2025 | 501 | CN 90 | 96.87 |
| Multiple and Secondary Primary Cancers | 2021-2025 | 82 | CN 12 | 92.27 |
| Cholangiocarcinoma and Gallbladder Cancer Studies | 2021-2025 | 328 | CN 65 | 94.54 |
| Pancreatic and Hepatic Oncology Research | 2021-2025 | 863 | CN 106 | 94.60 |
| HER2/EGFR in Cancer Research | 2021-2025 | 297 | CN 33 | 95.27 |
| Hepatocellular Carcinoma Treatment and Prognosis | 2021-2025 | 595 | CN 140 | 94.10 |
| Cancer Cells and Metastasis | 2021-2025 | 437 | CN 90 | 89.67 |
| Hepatitis B Virus Studies | 2021-2025 | 435 | CN 75 | 92.91 |
| Colorectal Cancer Treatments and Studies | 2021-2025 | 549 | CN 62 | 93.58 |
| Lung Cancer Diagnosis and Treatment | 2021-2025 | 950 | CN 211 | 92.32 |
| Melanoma and MAPK Pathways | 2021-2025 | 159 | CN 9 | 91.82 |
| Inflammatory Biomarkers in Disease Prognosis | 2021-2025 | 248 | CN 104 | 87.64 |
| Galectins and Cancer Biology | 2021-2025 | 165 | CN 39 | 87.18 |
| Bladder and Urothelial Cancer Treatments | 2021-2025 | 782 | CN 86 | 91.63 |
| Breast Cancer Treatment Studies | 2021-2025 | 802 | CN 60 | 91.68 |
| Spine and Intervertebral Disc Pathology | 2021-2025 | 973 | CN 206 | 91.40 |
| Biomarkers in Disease Mechanisms | 2021-2025 | 65 | CN 26 | 82.24 |
| Cancer, Lipids, and Metabolism | 2021-2025 | 725 | CN 289 | 86.29 |
| Advanced Breast Cancer Therapies | 2021-2025 | 606 | CN 54 | 88.98 |
| Autophagy in Disease and Therapy | 2021-2025 | 643 | CN 310 | 86.04 |
| Single-cell and spatial transcriptomics | 2021-2025 | 950 | CN 255 | 85.70 |
| Viral-associated cancers and disorders | 2021-2025 | 700 | CN 153 | 82.13 |
| PARP inhibition in cancer therapy | 2021-2025 | 833 | CN 85 | 80.12 |
| Wnt/β-catenin signaling in development and cancer | 2021-2025 | 162 | CN 39 | 74.53 |
| Kruppel-like factors research | 2021-2025 | 187 | CN 60 | 78.30 |
| Cancer Risks and Factors | 2021-2025 | 664 | CN 61 | 79.41 |
| Cancer, Stress, Anesthesia, and Immune Response | 2021-2025 | 347 | CN 137 | 73.87 |
| Toxin Mechanisms and Immunotoxins | 2021-2025 | 377 | CN 51 | 71.73 |
| NF-κB Signaling Pathways | 2021-2025 | 190 | CN 66 | 66.92 |
| Signaling Pathways in Disease | 2021-2025 | 367 | CN 144 | 64.83 |
| Heme Oxygenase-1 and Carbon Monoxide | 2021-2025 | 628 | CN 260 | 66.46 |
| Angiogenesis and VEGF in Cancer | 2021-2025 | 692 | CN 144 | 61.43 |
| Cell death mechanisms and regulation | 2021-2025 | 555 | CN 155 | 55.33 |
| Chemokine receptors and signaling | 2021-2025 | 955 | CN 158 | 45.82 |